Table 1.
Study Participant Demographic and Medical Characteristics
| Mean (SD) | Range | |
|---|---|---|
| Age (years) | 54.7 (12.5) | 22–78 |
| Education (years) | 16.2 (3.0) | 10–26 |
| Median | Range | |
| Time between diagnosis and Ax (weeks) | 4 | 1–13 |
| Time between chemoradiation start and Ax (weeks) | 1 | 0–4 |
| Dexamethasone dose per day (mg) | 2.5 | 0–16 |
| N(%) | ||
| Sex | ||
| Female | 12 (26.7) | |
| Male | 33 (73.3) | |
| Handedness | ||
| Right | 38 (84.4) | |
| Left | 3 (6.7) | |
| Did not report | 4 (8.9) | |
| Antidepressant and/or anxiolytic medication | ||
| Yes | 5 (11.1) | |
| No | 35 (66.7) | |
| Unknown | 10 (22.2) | |
| Premorbid history of depression | ||
| Yes | 2 (4.4) | |
| No | 43 (84.4) | |
| Unknown | 5 (11.1) | |
| Dexamethasone | ||
| Yes | 34 (75.5) | |
| No | 7 (15.5) | |
| Unknown | 4 (8.9) | |
| Extent of surgical resection | ||
| Total | 3 (6.7) | |
| Subtotal | 34 (75.6) | |
| Biopsy | 6 (13.3) | |
| Unknown | 2 (4.4) | |
| IDH Status | ||
| Mutated | 10 (22.2) | |
| Wildtype | 30 (66.7) | |
| Unknown | 5 (11.1) | |
| MGMT promoter methylation | ||
| Methylated | 16 (35.6) | |
| Unmethylated | 12 (26.7) | |
| Unknown | 17 (37.8) | |
| Tumor laterality | ||
| Right | 23 (51.1) | |
| Left | 19 (42.2) | |
| Bilateral | 3 (6.7) | |
| Tumor location | ||
| Frontal | 12 (26.7) | |
| Parietal | 11 (24.4) | |
| Temporal | 5 (11.1) | |
| Temporal-parietal | 5 (11.1) | |
| Frontoparietal | 4 (8.9) | |
| Occipital | 2 (4.4) | |
| Frontotemporal | 2 (4.4) | |
| Thalamus | 2 (4.4) | |
| Intraventricular | 1 (2.2) | |
| Multifocal | 1 (2.2) |
Abbreviations: Ax = neuropsychological assessment. IDH = Isocitrate Dehydrogenase; MGMT = 0[6]-methylguanine-DNA methyltransferase.